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Leader peptide exchange to produce hybrid, new-to-nature 
ribosomal natural products 
Laura Franza and Jesko Koehnke*a,b 
Ribosomal natural products contain exquisite post-translational 
peptide modifications that are installed by a range of pathway-
specific enzymes. We present proof of principle for a Sortase A-
based approach that enables peptide modifcation by enzymes from 
unrelated pathways. This allowed the one-pot synthesis of a new-
to-nature, hybrid ribosomal natural product. 
Natural products and their derivatives have been an invaluable, 
rich source for drugs.1, 2 In recent years, the fast-expanding 
superfamily of ribosomally synthesized and post-translationally 
modified peptide (RiPP) natural products has been recognised 
as a major source for novel compounds with potent biological 
(e.g. antibiotics) activities.3, 4 RiPP biosynthesis begins with the 
production of a short, ribosomally synthesized precursor 
peptide (PP), usually comprised of a N-terminal leader peptide 
(LP) and a C-terminal core peptide (CP) (Scheme 1).3, 4 While the 
LP is essential for binding (and activation) of the biosynthetic 
enzymes and typically discarded during biosynthesis, the CP is 
transformed into the mature RiPP. Primary RiPP enzymes 
require specific parts of the LP, or recognition sequences (RSs), 
for activity and introduce characteristic, RiPP class-defining 
post-translational modifications (PTMs) in the CP. The spatial 
separation of substrate recognition (LP) and the site of catalysis 
(CP) permits primary RiPP enzymes to be very promiscuous with 
respect to the CP sequence.3-11 Secondary RiPP enzymes do not 
depend on the LP and are responsible for specific tailoring steps. 
The PTMs introduced by primary enzymes are incredibly diverse 
and expand the chemical space accessible to RiPPs far beyond 
the 20 canonical amino acids that comprise the PP (ribosomal 
expression).3, 4 They include, but are not limited to, azol(in)e 
heterocycles, lanthionine-, sactionine-, C-C and ester-crosslinks, 
thioamidation, and N-methylation of the CP backbone.3, 4 These 
PTMs endow RiPPs with several desirable properties, including 
potent bioactivities. The ability to combine the primary 
enzymes from unrelated pathways could facilitate the 
generation of RiPP-inspired natural product libraries for drug 
discovery. It would require the attachment of different LPs to a 
given CP. 
To accomplish this feat, the initial focus had been on 
establishing conditions for LP-independent peptide processing. 
This was attempted by primary RiPP enzyme engineering, or by 
supplying the LP in trans.12-17 Recently, the improved 
understanding of RiPP enzymology was used in an inspired 
approach to engineer new to nature, hybrid RiPPs.18, 19 By 
packaging two RSs from different RiPP families into a single, 
chimeric LP it was possible to generate unprecedented 
molecules (Scheme S1, ESI). Thus far chimeric LPs have been 
limited to two RSs and the approach requires a thorough 
understanding of the substrate recognition requirements of 
each enzyme. We sought a less involved method, that would 
allow us to simply swap LPs between biosynthetic steps. This 
approach would allow iterative processing and not require a 
detailed understanding of the substrate recognition sequences 
required by the enzymes used, potentially making it plug-and-
play. Our leader peptide exchange (LPX) technique is based on 
sortase A (SrtA)-mediated transpeptidation (Scheme 2). 
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Scheme 1 Overview of RiPP biosynthesis. 
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To demonstrate the utility and feasibility of our idea we decided 
to generate a new-to-nature RiPP by combining enzymes from 
the unrelated cyanobactin and microviridin pathways (Fig. S1-
S2, ESI). The enzyme LynD is found in a cyanobactin pathway 
discovered in Lyngbya sp. and converts cysteine residues into 
thiazoline heterocycles during aesturamide biosynthesis (Fig. 
S1, ESI).13, 20 We chose to combine this heterocyclase with MdnC 
of the microviridin J (derived from PP MdnA) pathway found in 
Microcystis aeruginosa.21, 22 This enzyme catalyses the 
formation of two -ester bonds from Ser/Thr and Asp/Glu side 
chains, which leads to the formation of macrocycles (Fig. 
S2, ESI). An engineered variant of SrtA, SrtA7m,23 was chosen to 
facilitate LPX. We designed two synthetic peptides: Peptide 1 
was comprised of a truncated cyanobactin LP suitable for LynD, 
followed by the SrtA recognition motif (LPXTG), a di-glycine and 
the MdnA core peptide harbouring two point mutations (Ser2 
and Pro7 to Cys) (Fig. S3, ESI). Peptide 2 consisted of a truncated 
MdnA LP containing the MdnC RS and a C-terminal SrtA 
recognition motif (Fig. S3, ESI). To probe SrtA-mediated LPX, we 
incubated peptide 1 (All calculated and observed masses 
including mass errors can be found in Table S1, ESI) and peptide 
2 with SrtA7m (2 h, 37 °C) and analysed the reaction products by 
liquid chromatography-electrospray ionization-mass 
spectrometry (LC-ESI-MS). We readily detected the desired 
reaction product, peptide 3 (Fig. S4, ESI). Since the SrtA7m 
reaction is an equilibrium, we also detected the other expected 
masses (Fig. S4). Several techniques have been developed to 
pull the SrtA7m equilibrium into the desired direction and may 
be employed to optimize this system in the future.24, 25 
With LPX successfully established, we next tested the tolerance 
of LynD and MdnC for the presence of the SrtA recognition 
sequence that we had introduced. Incubation of peptide 1 with 
LynD in the presence of ATP/Mg2+ led to an observed loss of 36 
Da, which is in agreement with the desired two 
cyclodehydration reactions required to convert the two CP Cys 
residues into thiazolines (Fig. S5, ESI). Treatment of this reaction 
product with iodoacetamide, which alkylates free Cys residues, 
did not result in a mass shift. This strongly implies the 
conversion of the two Cys residues to thiazolines in the LynD-
treated peptide (4) (Fig. S5, ESI). Incubation of peptide 3 with 
MdnC in the presence of ATP/Mg2+ also resulted in the expected 
loss of 36 Da. This is in agreement with the formation of two -
ester bonds in peptide 3 (Fig. S6, ESI). These data confirm the 
compatibility of both enzymes with the SrtA recognition 
sequence and highlights the malleability of RiPP systems. 
With all components of our model system tested, we combined 
them in one pot. After incubation of peptide 1 with LynD and 
ATP/Mg2+, SrtA7m was added and we rapidly observed the 
liberation of the core peptide with two thiazolines (6) (Fig. 1 III. 
and Fig. S7, ESI). After addition of peptide 2, the SrtA-mediated 
ligation product with 6 was observed (7, Fig. 1 IV. and Fig. S7, 
ESI). Subsequent addition of MdnC led to another loss of 36 Da, 
indicating that MdnC tolerates the two non-natural thiazolines 
in the core peptide and introduces two -esters into the 
peptide (8, Fig. 1 V. and Fig. S7, ESI). Since SrtA7m was not 
removed, the MdnA LP was cleaved by SrtA7m and we obtained 
a new to nature, hybrid RiPP 9 (Fig. 1 V. and Fig. S7, ESI). 
Verification of the -ester connectivity was attempted via 
methanolysis of 9, but the peptide was completely insoluble in 
methanol. Very extensive peptide MS/MS did not resolve this 
issue either, presumable because the combination of 
heterocycles with -ester bonds made the peptide very 
resistant to fragmentation. We therefore view the structure of 
9 as tentative. Reactions without the addition of SrtA stalled 
after the introduction of the two thiazolines and did not result 
in -ester formation, or the production of 9. To the best of our 
knowledge, 9 represents the first heterocycle-containing 
graspetide, the newly coined name for microviridins and related 
compounds.4 
We have demonstrated that the SrtA-based LPX technique is 
compatible with RiPP enzymes. Since our approach dispenses 
with the need for a detailed understanding of enzyme-substrate 
recognition for a particular enzyme / pathway, it has the 
potential to greatly expedite the creation of hybrid RiPPs. It is 
going to be important to consider the combination of enzymes 
used when designing this approach. In the case presented here 
we used LynD before MdnC, because it was reasonable to 
assume that the topology introduced by MdnC would preclude 
processing of the cysteine residues by LynD. In addition, we 
selected LynD because it is specific to cysteine residues and 
leaves Ser/Thr available for MdnC. The use of other 
heterocyclases that are able to convert Ser/Thr residues to 
oxazolines would preclude MdnC from forming -esters. 
Depending on the timing of addition, this could also lead to 
competition for reaction sites that would reduce yields and 
complicate analysis. It could of course also be viewed as an 
Scheme 2 The leader peptide exchange (LPX) strategy enables Sortase A (SrtA, red)-
mediated LPX and thus iterative core peptide processing by biosynthetic enzymes of 
different RiPP classes. A final step using SrtA or another protease liberates the hybrid 
RiPP. SrtA recognition sequence is shown in red, di-Gly linker in magenta. Symbols (e.g. 
stars) represent PTMs. 
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opportunity to generate a set of products from a single reaction, 
which may yield unexpected, interesting candidates for a given 
activity screen. The protection of side-chains may offer a 
solution to this issue, but would then require the purification of 
intermediates prior to addition of the next RiPP enzyme. In this 
context it is going to be interesting to trial this approach with 
RiPPs that depend on a particular sequence N-terminal of the 
core peptide for proper processing, such as cyclization, for 
example in azacycle formation during thiopeptide biosynthesis. 
Depending on the desired outcome, it may be necessary to 
include the native protease site between the SrtA recognition 
sequence and the core peptide. It may be of particular interest 
to use the LPX approach in combination with self-sacrificing 
RiPP enzymes, such as the backbone N-methylating enzyme 
OphA26, which cannot be combined with other leader-
dependent RiPP enzymes through hybrid leader peptides. 
We focussed our efforts on proof-of-concept and thus did not 
attempt to maximise reaction yields. The two main aspects that 
would improve yields are 1. the use of optimized SrtA 
substrates, which have been specifically developed to drive the 
ligation reaction in the desired reaction and 2. the inactivation 
or removal of SrtA or the SrtA-substrate complex prior to 
addition of the second enzyme (compare Figure S7). A large 
variety of tools to accomplish the former task have been 
developed and established for SrtA and will be used in future 
studies. The latter point arose because the active SrtA7m in the 
reaction led to a competition with MdnC.  
Truncated leader peptides were used here to reduce synthesis 
costs, but full-length leader peptides are of course compatible. 
Intriguingly, the peptides used as starting material in this study 
can of course be produced ribosomally, for example through 
expression in Escherichia coli. As a consequence the entire 
system could be moved into an in vivo setting. While the yields 
of in vivo ligation reactions using SrtA are not ideal, it would 
allow the leverage of genetics to create large libraries based on 
core peptide randomization. In targeted bioactivity screens the 
Fig. 1 Combination of the cyanobactin heterocyclase LynD and the microviridn J ATP-grasp ligase MdnC using the LPX strategy to produce a heterocycle-containing graspetide (9). A 
Schematic of the LPX model system. After introduction of the thiazolines (blue pentagons) in 1 by LynD, the LynD LP is exchanged for the MdnA LP (2) using SrtA-mediated 
transpeptidation yielding 7. LPX allows the modification of the core peptide (black) by MdnC that introduces two -ester cross-links (8). SrtA finally cleaves the MdnA LP yielding the 
new-to-nature hybrid RiPP 9. B Extracted ion chromatograms (EICs, ±5 ppm) and mass spectra for the desired products of each step shown in A. Shown are the masses of the singly-
charged monoisotopic ions [M+H]+. An extensive presentation of all products and secondary products (SrtA reactions are reversible) in all steps (I.-V.) is given in the ESI, Fig. S7.
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in vivo efficiency of SrtA may well prove sufficient to discover 
novel, exciting molecules. 
Conflicts of interest 
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